TCP provides cytopathology review of cases submitted for the Afirma Genomic Sequencing Classifier. As members of the largest, thyroid-specialized cytopathology practice, TCP pathologists adhere to the established Bethesda criteria, which facilitate clear, definitive and confident cytopathology diagnoses.
† For nodules diagnosed as indeterminate*, the
Afirma Genomic Sequencing Classifier (GSC) is applied and can
objectively reclassify these cases as either benign
1 or suspicious for malignancy. And, when you receive an Afirma GSC Suspicious result or a Bethesda V or VI cytopathology result, adding the
Afirma Xpression Atlas (XA) can provide additional genomic content to help inform surgery decisions and treatment options.